Top Endoscope Companies

Global Endoscope Market size was valued at USD 23.46 Billion in 2024 and is poised to grow from USD 24.68 Billion in 2025 to USD 37.02 Billion by 2033, growing at a CAGR of 5.2% during the forecast period (2026–2033). 

The global endoscope market has high competition due to the presence of prominent players who apply various strategies to expand their market share and dominate the market. Some key players include Olympus Corporation, KARL STORZ SE & Co. KG, Stryker Corporation, Boston Scientific Corporation, JOHNSON & JOHNSON, and Fujifilm Holdings Corporation. The market's leading players are looking forward to increasing their investments in the creation of advanced devices and fulfill the increasing demand for endoscopy devices. 'Olympus Corporation (Japan) ', 'Stryker Corporation (US) ', 'Medtronic (Ireland) ', 'Ethicon Endo-Surgery, Inc (US) ', 'Aesculap, Inc (Germany) ', 'Arthrex, Inc. (US) ', 'Smiths Group (UK) ', 'Karl Storz (Germany) ', 'Richard Wolf GmbH (Germany) ', 'Ambu A/S (Denmark) ', 'STERIS plc (Ireland) ', 'Fujifilm Holdings Corporation (Japan)'

Surge in the prevalence of chronic disorders and the increasing awareness regarding early diagnosis of diseases through minimally invasive surgical techniques are the key drivers expected to propel the market growth.

Artificial intelligence is expected to boost the adoption of capsule endoscopy. The incorporation of several technological advancements into capsule endoscopy to improve reading efficiency, accuracy, and diagnostic capabilities is projected to fuel market growth.

North America accounted for the largest share of the global endoscope market and is expected to maintain its dominance during the forecast period. It accounted for more than 41% share of the total revenue worldwide. This can be attributed to the rising elderly population, increased healthcare spending, and growing use of elective endoscopic treatments. Intensification of preventive healthcare initiatives, appearance of highly advanced healthcare organisations, and supportive reimbursement environments are driving the market expansion in this region. Over the course of the forecast period, it is also projected that the increasing prevalence of cancer and functional gastrointestinal disorders in the U.S. will further propel the market growth. Moreover, the American Cancer society also predicted that 1.9 million new cancer patients will be diagnosed in 2021 in U.S. These factors will drive the market growth in this region.